A three-part, randomized, placebo-controlled, pharmacokinetic and safety trial of multiple doses of oral CR 845 in hemodialysis patients

Trial Profile

A three-part, randomized, placebo-controlled, pharmacokinetic and safety trial of multiple doses of oral CR 845 in hemodialysis patients

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Difelikefalin (Primary) ; Difelikefalin
  • Indications Pruritus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Jul 2017 Status changed from recruiting to completed as per Cara Therapeutics media release
    • 12 Jul 2017 According to a Cara Therapeutics media release, the data from this trial will help to initiate a clinical trial of an oral CR845 pruritus in the non-dialysis CKD-associated pruritus patients in 2017.
    • 12 Jul 2017 Top line results are published in the Cara Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top